|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
37.66 USD |
+0.59% | -6.74% | -13.90% | |
Published on 05/07/2025 at 17:04
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Revolution Medicines Q1 Net Loss Widens |
05:04pm |
MT |
|
Earnings Flash (RVMD) Revolution Medicines Q1 Loss $1.13 Vs. FactSet Est. Loss $1.10 |
04:49pm |
MT |
|
Sector Update: Health Care Stocks Swing Between Small Gains, Losses |
Apr. 28 |
MT |
|
Revolution Medicines Shares Rise on ‘Encouraging’ Phase 1 Lung Cancer Trial Data |
Apr. 28 |
MT |
|
Revolution Medicines, Inc. Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting |
Apr. 27 |
CI |
|
Small to Mid-Cap Biotechnology Firms Likely to Continue to Face Macro Headwinds, BofA Securities Says |
Apr. 03 |
MT |
|
Revolution Medicines, Inc. Presents at Barclays 27th Annual Global Healthcare Conference 2025, Mar-11-2025 08:00 AM |
Mar. 11 |
|
|
Revolution Medicines Q4 Net Loss Narrows |
Feb. 26 |
MT |
|
Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99 |
Feb. 26 |
MT |
|
Revolution Medicines, Inc., Q4 2024 Earnings Call, Feb 26, 2025 |
Feb. 26 |
|
|
Revolution Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 |
Feb. 26 |
CI |
|
Revolution Medicines, Inc. Provides Earnings Guidance for the Full Year 2025 |
Feb. 26 |
CI |
|
Certain Restricted Stock Units of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. |
Jan. 17 |
CI |
|
Certain Stock Options of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. |
Jan. 17 |
CI |
|
Certain Common Stock of Revolution Medicines, Inc. are subject to a Lock-Up Agreement Ending on 18-JAN-2025. |
Jan. 17 |
CI |
|
Revolution Medicines, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 10:30 AM |
Jan. 13 |
|
|
UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating |
Jan. 08 |
MT |
|
Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating |
Dec. 06 |
MT |
|
Revolution Medicines Closes Offering of 16.6 Million Shares |
Dec. 05 |
MT |
|
Revolution Medicines Prices $45 Million Stock, Warrant Offering |
Dec. 04 |
MT |
|
Revolution Medicines Launches $600 Million Offering of Common Shares |
Dec. 02 |
MT |
|
Sector Update: Health Care Stocks Slipping Late Afternoon |
Dec. 02 |
MT |
|
Sector Update: Health Care |
Dec. 02 |
MT |
|
Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating |
Dec. 02 |
MT |
|
Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies |
Dec. 02 |
MT |
RVMD: Dynamic Chart
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
More about the company
Buy
Average target price
72.33USD
Spread / Average Target
+93.20%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
